| dc.degree.name |
Recombinant human adenovirus (Ad) vectors are being extensively explored for their use
in gene therapy and recombinant vaccines. Ad vectors are attractive for many reasons, including
the fact that (1) they are relatively safe, based on their use as live oral vaccines, (2) they can
accept large transgene inserts, (3) they can infect dividing and postmitotic cells, and (4) they can
be produced to high titers. However, there are also a number of major problems associated with
Ad vectors, including transient foreign gene expression due to host cellular immune responses,
problems with humoral immunity, and the creation of replication competent adenoviruses
(RCA).
Most Ad vectors contain deletions in the E1 region that allow for insertion of a transgene.
However, the E1 gene products are required for replication and thus must be supplied in trans by
a helper ceillille that will allow for the growth and packaging of the defective virus. For this
purpose the 293 cell line (Graham et al., 1977) is used most often; however, homologous
recombination between the vector and the cell line often results in the generation of RCA. The
presence of RCA in batches of adenoviral vectors for clinical use is a safety risk because tlley
. may result in the mobilization and spread of the replication-defective vector viruses, and in
significant tissue damage and pathogenicity. The present research focused on the alteration of
the 293 cell line such that RCA formation can be eliminated.
The strategy to modify the 293 cells involved the removal of the first 380 bp of the
adenovirus genome through the process of homologous recombination. The first step towards
this goal involved identifying and cloning the left-end cellular-viral jUl1ction from 293 cells to
assemble sequences required for homologous recombination. Polymerase chain reaction (PCR)
was performed to clone the junction, and the clone was verified through sequencing. The
plasn1id PAM2 was then constructed, which served as the targeting cassette used to modify the
293 cells. The cassette consisted of (1) the cellular-viral junction as the left-end region of
homology, (2) the neo gene to use for positive selection upon tranfection into 293 cells, (3) the
adenoviral genome from bp 380 to bp 3438 as the right-end region of homology, and (4) the
HSV-tk gene to use for negative selection.
The plasmid PAM2 was linearized to produce a double strand break outside the region of
homology, and transfected into 293 cells using the calcium-phosphate technique. Cells were first
selected for their resistance to the drug G418, and subsequently for their resistance to the drug
Gancyclovir (GANC). From 17 transfections, 100 pools of G418f and GANCf cells were picked
using cloning lings and expanded for screening. Genomic DNA was isolated from the pools and
screened for the presence of the 380 bps using PCR. Ten of the most promising pools were
diluted to single cells and expanded in order to isolate homogeneous cell lines. From these, an
additional 100 G41Sf and GANef foci were screened. These preliminary screening results
appear promising for the detection of the desired cell line. Future work would include further
cloning and purification of the promising cell lines that have potentially undergone homologous
recombination, in order to isolate a homogeneous cell line of interest. |
en_US |